[Efficacy of zonisamide in Lafora's disease case and brief review of its use in progressive myoclonic epilepsy].

Abstract

INTRODUCTION:

Mioclonic progressive epilepsy (MPE) includes a clinical and genetical heterogeneous group of neuro-degenerative disorders that associate spontaneous and action-induced myoclonus as well as progressive cognitive impairment. Lafora`s disease is a subtype of MPE with autosomical recessive inheritance due to a mutation in EPM2A or EPM2B genes. Seizures, especially myoclonus, are often refractary to antiepileptic drugs (AD).

CASE REPORT:

In this article we report a patient with Lafora´s disease diagnosis, previously resistant to several AD tested with good and sustained response to zonisamide. Indeed, we describe a brief review about the efficacy of zonisamida in MPE.

CONCLUSION:

Zonisamide may be considered as a good therapeutic alternative in MPE.

• Authors: E Rubio-Nazábal, P Álvarez-Pérez, C Cores-Bartolomé, T Lema-Facal
• Journal: Revista de neurologia (Rev Neurol) Vol. 75 Issue 6 Pg. 159-163 (09 16 2022) ISSN: 1576-6578 [Electronic] Spain
• Vernacular Title: Eficacia de la zonisamida en un caso de enfermedad de Lafora y breve revisión en la epilepsia mioclónica progresiva.
• PMID: 36098450 (Publication Type: Case Reports, Review)

Chemical References

• Anticonvulsants
• Zonisamide

Topics

• Anticonvulsants (therapeutic use)
• Humans
• Lafora Disease (diagnosis, drug therapy, genetics)
• Myoclonic Epilepsies, Progressive (drug therapy, genetics)
• Myoclonus
• Zonisamide (therapeutic use)